Showing posts with label Diagnosis. Show all posts
Showing posts with label Diagnosis. Show all posts

Sunday, September 4, 2011

WHO calls for ban on 'unreliable' TB blood tests

Posted: 21 July 2011


Blood tests
GENEVA: The World Health Organisation warned on Wednesday that millions of blood tests conducted every year to diagnose tuberculosis are unreliable and putting patients' lives in danger.

"Based on the evidence, (these) tests lead to misdiagnosis and mistreatment of patients. They are a waste of time and resources," Mario Raviglione, director of the WHO Stop TB Department, told reporters.

"We are calling on governments to ban the use of these tests."

An estimated two million such diagnostics, which look for antibodies or antigens in the blood, are used every year, and up to half of them could give false results, Karin Weyer, who works for the same department, said.

She warned that companies which continued to sell these diagnostic tools would be knowingly selling a faulty product.

"This is now a matter of public record," she said, adding however that the WHO did not know how many deaths resulted from these unreliable tests, which started being released in the 1990s.

They are mostly manufactured by companies based in the developed world, including Australia, Britain, Canada, France, Germany, Italy and the United States, but also in emerging giants China and India.

A list of companies pinpointed by the WHO includes US-based Mossman Associates, French group Anda Biologicals and British firm Omega Diagnostics.

"They cost the poor and vulnerable $10 to $30. And yet more often than not, the results are wrong," Raviglione said.

Other types of diagnostics, which cost between $16 and $28 give more reliable results, Raviglione said.

One of the reasons these tests are in the market is because of lack of regulations, Weyer explained.

"It's a multi-million dollar business centred on selling substandard tests with unreliable results.

"The market for these products is not in Europe or the US, but in developing countries.

"These companies just ship (the tests) to developing countries with weak or no regulatory framework," concluded Weyer.

According to the WHO website, there are some 9.4 million new cases of active TB and 1.7 million people who are killed by the transmissible disease every year.

- AFP/al



Taken from ChannelNewsAsia.com; source article is below:
WHO calls for ban on 'unreliable' TB blood tests


Enhanced by Zemanta

Thursday, March 18, 2010

Omega 3 and bowel cancer

Main symptoms of cancer metastasis. Sources ar...Image via Wikipedia
Omega 3 supplement targets bowel cancer risk: study
AFP - Thursday, March 18


PARIS (AFP) - A purified form of omega 3, the so-called "good fat" found naturally in certain fish and nut oils, reduced dangerous polyps among people prone to bowel cancer, a study published on Thursday says.

Fifty patients were enrolled in the investigation, all with a genetic mutation that prompts the development of polyps -- precancerous growths in the bowel that often develop into tumours requiring removal of large sections of intestine.

Twenty-eight were randomly assigned to a group that received a two-gramme daily dose of a new, highly purified form of omega 3, while the other 27 were given a dummy lookalike, or placebo.

After six months, the number of polyps had risen by almost 10 percent among the placebo group but fell by 12 percent for those taking the omega 3 capsules, amounting to a difference of more than 22 percent.



-----
A purified form of omega 3, the so-called "good fat" found naturally in certain fish, such as salmon (pictured), and nut oils, reduced dangerous polyps among people prone to bowel cancer, according to a new study.
-----


In addition, polyp size increased by 17 percent among the placebo takers, whereas it decreased by 12.5 percent in the capsule group, a difference of just under 30 percent.

These results are similar to a drug called celecoxib, marketed as Celebrex, which is used to inhibit polyps among genetically vulnerable patients.

However, celecoxib has been linked to cardiovascular side effects among older patients. In contrast, the omega 3 -- full name eicosapentaeonic acid, or EPA -- supplement was "very well tolerated," say the doctors.

The paper is published online by Gut, a journal of the British Medical Association (BMA).


From Yahoo.sg News; see the source article here.
----------